RELMADA THERAPEUTICS, INC. (RLMD)
$0.00+$0.00 (+0.00%) Latest sessionExtended Hours
Latest RLMD Insider Trades
Maged Shenouda - OfficerOpen-market purchase
Maged Shenouda - OfficerMaged Shenouda - OfficerMaged Shenouda - OfficerMaged Shenouda - OfficerRelmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 4 | 400,000 | $1.67M |
16 Form 4 filings on record, the earliest from Oct 23, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Maged Shenouda - Officer | Open-market purchase | Common Stock | 120,200 | $4.20 | $505K | |
| Maged Shenouda - Officer | Open-market purchase | Common Stock | 79,800 | $4.25 | $339K | |
| Sergio Traversa - Officer | Open-market purchase | Common Stock | 100,000 | $4.18 | $418K | |
| Sergio Traversa - Officer | Open-market purchase | Common Stock | 100,000 | $4.10 | $410K | |
| Sergio Traversa - Officer | Open-market purchase | Common Stock | 27,500 | $4.12 | $113K | |
| Sergio Traversa - Officer | Grant or award | Stock Appreciation Rights | 1,198,000 | $0.00 | - | |
| Maged Shenouda - Officer | Open-market purchase | Common Stock | 11,665 | $4.12 | $48K | |
| Maged Shenouda - Officer | Grant or award | Stock Appreciation Rights | 828,000 | $0.00 | - | |
| Paul Edward Kelly - Officer | Grant or award | Stock Appreciation Rights | 828,000 | $0.00 | - | |
| Charles J. Casamento - Director | Grant or award | Stock Appreciation Rights | 164,000 | $0.00 | - | |
| Chuck Ence - Officer | Grant or award | Stock Appreciation Rights | 828,000 | $0.00 | - | |
| John Glasspool - Director | Grant or award | Stock Appreciation Rights | 164,000 | $0.00 | - | |
| Fabiana Fedeli - Director | Grant or award | Stock Appreciation Rights | 164,000 | $0.00 | - | |
| Sergio Traversa - Officer | Open-market purchase | Common Stock | 272,500 | $2.20 | $600K | |
| Maged Shenouda - Officer | Open-market purchase | Common Stock | 500,000 | $2.20 | $1.10M | |
| Paul Edward Kelly - Officer | Open-market purchase | Common Stock | 90,000 | $2.20 | $198K | |
| Chuck Ence - Officer | Open-market purchase | Common Stock | 136,000 | $2.20 | $299K | |
| Sergio Traversa - Officer | Open-market purchase | Common Stock | 80,545 | $0.62 | $50K | |
| Sergio Traversa - Officer | Open-market purchase | Common Stock | 129,455 | $0.67 | $87K | |
| Sergio Traversa - Officer | Open-market purchase | Common Stock | 55,976 | $0.74 | $41K | |
| Charles J. Casamento - Director | Grant or award | Stock Option (right to buy) | 100,000 | $0.00 | - | |
| Charles J. Casamento - Director | Gift | Common Stock | 13,000 | $0.00 | - |
RELMADA THERAPEUTICS, INC. (RLMD) had 2 insider filings in the last 90 days, with the most recent on 2026-09-11. The full record for RLMD runs to 16 Form 4 filings, the earliest from 2024-10-23. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
4 insider purchases of RLMD were filed in the last 90 days, totaling $1.67M.
No insider sales of RLMD were filed in the last 90 days.
This page tracks RLMD Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add RLMD to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
